ZINC SULFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zinc Sulfate, and what generic alternatives are available?
Zinc Sulfate is a drug marketed by Abraxis Pharm, Am Regent, Fresenius Kabi Usa, Gland Pharma Ltd, and Zydus Pharms. and is included in five NDAs.
The generic ingredient in ZINC SULFATE is zinc sulfate. There are thirty-eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the zinc sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zinc Sulfate
A generic version of ZINC SULFATE was approved as zinc sulfate by AM REGENT on July 18th, 2019.
Summary for ZINC SULFATE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 48 |
Clinical Trials: | 1,055 |
Patent Applications: | 1,407 |
Formulation / Manufacturing: | see details |
Drug Sales Revenues: | Drug sales revenues for ZINC SULFATE |
What excipients (inactive ingredients) are in ZINC SULFATE? | ZINC SULFATE excipients list |
DailyMed Link: | ZINC SULFATE at DailyMed |
Recent Clinical Trials for ZINC SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wake Forest University Health Sciences | Phase 3 |
Cukurova University | Phase 4 |
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited | Phase 1 |
Pharmacology for ZINC SULFATE
Drug Class | Copper Absorption Inhibitor |
Physiological Effect | Decreased Copper Ion Absorption |